S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

CompanyDateActionBrokerageRatingPrice TargetImpact on PriceActions
DMTK
DermTech
9/11/2020Initiated byBrookline Capital ManagementBuyHigh    
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
9/3/2020Initiated byBrookline Capital ManagementBuy $33.00Low    
MDNA
Medicenna Therapeutics
8/24/2020Reiterated byBrookline Capital ManagementBuyMedium    
FBRX
Forte Biosciences
8/28/2020Initiated byBrookline Capital ManagementBuy $90.00Low    
HUGE
Fsd Pharma
8/20/2020Reiterated byBrookline Capital ManagementBuyLow    
HUGE
FSD Pharma
8/20/2020Initiated byBrookline Capital ManagementBuy $11.00N/A    
Kura Oncology logo
KURA
Kura Oncology
8/16/2020Reiterated byBrookline Capital ManagementBuyLow    
NMTR
9 Meters Biopharma
8/18/2020Initiated byBrookline Capital ManagementBuy $5.00High    
Veru logo
VERU
Veru
8/14/2020Reiterated byBrookline Capital ManagementBuyLow    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
8/11/2020Reiterated byBrookline Capital ManagementBuyLow    
Miragen Therapeutics logo
MGEN
Miragen Therapeutics
7/21/2020Initiated byBrookline Capital ManagementBuy $6.00High    
ATE
Antibe Therapeutics
7/15/2020Reiterated byBrookline Capital ManagementBuyN/A    
MRNA
Moderna
7/13/2020Reiterated byBrookline Capital ManagementBuy $95.00High    
ASRT
Assertio Therapeutics
6/3/2020Initiated byBrookline Capital ManagementBuy $3.50Low    
CWBR
Cohbar
5/27/2020Reiterated byBrookline Capital ManagementBuyMedium    
CWBR
CohBar
5/28/2020Initiated byBrookline Capital ManagementBuyN/A    
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
5/25/2020Initiated byBrookline Capital ManagementBuy $7.00High    
Cyclacel Pharmaceuticals logo
CYCC
Cyclacel Pharmaceuticals
5/19/2020Initiated byBrookline Capital ManagementBuy $22.00High    
Biocept logo
BIOC
Biocept
5/14/2020Initiated byBrookline Capital ManagementBuyHigh    
OTLK
Outlook Therapeutics
5/5/2020Initiated byBrookline Capital ManagementBuyHigh    
Dare Bioscience logo
DARE
Dare Bioscience
4/28/2020Initiated byBrookline Capital ManagementBuy $7.50High    
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
4/14/2020Initiated byBrookline Capital ManagementBuy $35.00Low    
EDSA
Edesa Biotech
3/30/2020Initiated byBrookline Capital ManagementBuy $10.00High    
CLPT
MRI Interventions
3/11/2020Reiterated byBrookline Capital ManagementBuyHigh    
ARMP
AmpliPhi Biosciences
3/13/2020Reiterated byBrookline Capital ManagementBuyHigh    
CLPT
ClearPoint Neuro
3/12/2020Initiated byBrookline Capital ManagementBuy $15.00N/A    
MNPR
Monopar Therapeutics
2/19/2020Initiated byBrookline Capital ManagementBuy $42.00High    
BIOX
Bioceres Crop Solutions
2/4/2020Reiterated byBrookline Capital ManagementBuyLow    
BCDA
Biocardia
11/26/2019Reiterated byBrookline Capital ManagementBuyLow    
BCDA
BioCardia
11/26/2019Initiated byBrookline Capital ManagementBuy $22.00Low    
MDNA
Medicenna Therapeutics
11/19/2019Reiterated byBrookline Capital ManagementBuy C$4.00N/A    
BCEL
Atreca
8/20/2019Reiterated byBrookline Capital ManagementBuyHigh    
SCYNEXIS logo
SCYX
SCYNEXIS
8/19/2019Reiterated byBrookline Capital ManagementBuyHigh    
Vaxart logo
VXRT
Vaxart
8/15/2019Initiated byBrookline Capital ManagementBuy $6.00Low    
Celsion logo
CLSN
Celsion
7/25/2019Reiterated byBrookline Capital ManagementBuyMedium    
Chiasma logo
CHMA
Chiasma
7/24/2019Reiterated byBrookline Capital ManagementBuyLow    
Veru logo
VERU
Veru
7/29/2019Initiated byBrookline Capital ManagementBuy $12.00High    
Heat Biologics logo
HTBX
Heat Biologics
7/29/2019Initiated byBrookline Capital ManagementBuy$8.00 -> $8.00High    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
7/29/2019Initiated byBrookline Capital ManagementBuy$6.00 -> $6.00High    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
7/24/2019Reiterated byBrookline Capital ManagementBuyHigh    
QBIO
Q BioMed
5/10/2019Reiterated byBrookline Capital ManagementBuyLow    
Chiasma logo
CHMA
Chiasma
2/6/2019Reiterated byBrookline Capital ManagementBuyLow    
SCYNEXIS logo
SCYX
SCYNEXIS
1/4/2019Reiterated byBrookline Capital ManagementBuyHigh    
REXN
Rexahn Pharmaceuticals
11/27/2018Reiterated byBrookline Capital ManagementBuyN/A    
Celsion logo
CLSN
Celsion
11/20/2018Reiterated byBrookline Capital ManagementBuyMedium    
Cellectar Biosciences logo
CLRB
Cellectar Biosciences
11/20/2018Reiterated byBrookline Capital ManagementBuyLow    
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
9/27/2018Reiterated byBrookline Capital ManagementBuyLow    
Heat Biologics logo
HTBX
Heat Biologics
8/1/2018Reiterated byBrookline Capital ManagementBuyLow    
Histogenics logo
HSGX
Histogenics
8/1/2018Reiterated byBrookline Capital ManagementBuyMedium    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
7/27/2018Downgraded byBrookline Capital ManagementBuy -> HoldLow    
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
6/26/2018Reiterated byBrookline Capital ManagementBuyMedium    
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
5/1/2018Reiterated byBrookline Capital ManagementBuyLow    
CSV / Excel Export To export this table to CSV or Excel, upgrade to MarketBeat All Access.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17,695 (Vote Outperform)
Underperform Votes:  24,486 (Vote Underperform)
Total Votes:  42,181
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.